公开(公告)号：BRPI0622277A2

公开(公告)日：2011-08-09

申请号：BRPI0622277

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A61K31/519 ,  A61P37/00 ,  C07D487/00 ,  C07D487/04

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：MX2011000661A

公开(公告)日：2011-05-25

申请号：MX2011000661

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID

IPC: A61K31/52 ,  A61P35/00

Abstract: Descritos en la presente, son compuestos inhibidores de Btk irreversibles, y métodos para el uso de dichos inhibidores irreversibles, en el tratamiento de enfermedades y trastornos caracterizados por la presencia o el desarrollo de tumores sólidos.

公开(公告)号：AU2009270856A8

公开(公告)日：2011-03-03

申请号：AU2009270856

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  CHEN WEI ,  BUGGY JOSEPH ,  LOURY DAVID ,  VERNER ERIK

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：AU2010201052A1

公开(公告)日：2010-04-08

申请号：AU2010201052

申请日：2010-03-18

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  PAN ZHENGYING ,  VERNER ERIK

IPC: C07D471/04 ,  A01N43/90 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：CA2730930A1

公开(公告)日：2010-01-21

申请号：CA2730930

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：CA2721218A1

公开(公告)日：2009-10-22

申请号：CA2721218

申请日：2009-04-15

Applicant: PHARMACYCLICS INC

Inventor： VERNER ERIK ,  BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH J

IPC: C07D235/06 ,  C07D235/08 ,  C07D235/10 ,  C07D235/12 ,  C07D235/14

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the acitivy of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.

公开(公告)号：CA2874756C

公开(公告)日：2018-05-29

申请号：CA2874756

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C12N9/12 ,  C12Q1/48 ,  G01N33/53

Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

公开(公告)号：ES2627820T3

公开(公告)日：2017-07-31

申请号：ES11872389

申请日：2011-09-13

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID ,  BUGGY JOSEPH ,  MODY TARAK ,  VERNER ERIK ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STÉPHANE

IPC: A61K31/343 ,  A61K31/16 ,  A61K31/166 ,  A61P35/00

Abstract: Una combinación de bendamustina, o su sal de clorhidrato, y el Compuesto 1: Compuesto 1 o una sal **Fórmula** farmacéuticamente aceptable del mismo.

公开(公告)号：ES2616789T3

公开(公告)日：2017-06-14

申请号：ES12166300

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A01N43/90 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04

Abstract: Procedimiento para preparar compuestos de fórmula 4, 13 and 14: **Fórmula** por conversión a partir de un compuesto de fórmula 3: **Fórmula**

公开(公告)号：CY1116295T1

公开(公告)日：2017-02-08

申请号：CY151100453

申请日：2015-05-20

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING ,  MODY TARAK

IPC: A61K31/00 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Γνωστοποιούνταιστοπαρόνενώσειςοιοποίεςσχηματίζουνομοιοπολικούςδεσμούςμεκινάσητυροσίνηςτου Bruton (Btk). Επίσηςπεριγράφονταιστοπαρόνμη-αντιστρεπτοίαναστολείςτης Btk. Μέθοδοιγιατηνπαρασκευήτωνενώσεωνγνωστοποιούνται. Επίσηςγνωστοποιούνταιφαρμακευτικέςσυνθέσειςοιοποίεςπεριλαμβάνουντιςενώσεις. Μέθοδοιχρήσηςτων Btk αναστολέωνγνωστοποιούνται, μόνωνή σεσυνδυασμόμεάλλουςθεραπευτικούςπαράγοντες, γιατηναντιμετώπισηδιαταραχώντουπολλαπλασιασμούτωνΒ-κυττάρων.